Mycophenolate Mofetil

• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended
  2023-503999-24-00 Phase III 6 countries AstraZeneca AB
• New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended
  2023-510054-16-00 Phase II 7 countries Assistance Publique Hopitaux De Paris
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended
  2023-507342-84-00 Phase III 9 countries Astrazeneca AB
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended
  2022-503105-38-00 Phase III 8 countries AstraZeneca AB
• Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, Unresectable ESCC Ended
  2023-506413-22-00 Phase III 4 countries Astrazeneca AB
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended
  2023-507338-26-00 Phase III 8 countries Astrazeneca AB
• DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o… Ended
  2023-505309-18-00 Phase I/II 4 countries AstraZeneca AB
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended
  2022-502746-27-00 Phase III 8 countries AstraZeneca AB
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended
  2023-503628-22-00 Phase III 5 countries F. Hoffmann-La Roche AG
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu… Ended
  2023-504624-25-00 Phase II 5 countries AstraZeneca AB
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended
  2023-507405-34-00 Phase III 4 countries Astrazeneca AB
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime… Ended
  2024-512667-31-00 Phase III 8 countries AstraZeneca AB
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended
  2023-509576-42-00 Phase III 9 countries AstraZeneca AB
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended
  2023-509602-29-00 Phase III 7 countries AstraZeneca AB
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended
  2023-510015-19-00 Phase III 8 countries AstraZeneca AB
• STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended
  2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri… Ended
  2024-510976-19-00 Phase III 6 countries AstraZeneca AB
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos… Ended
  2023-505341-23-00 Phase III 7 countries AstraZeneca AB
• Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. Ended
  2023-509004-15-00 Phase II/III 4 countries AstraZeneca AB
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended
  2024-512470-10-00 Phase III/IV 1 country Centre Hospitalier Departemental Vendee
• This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, … Ended
  2024-512212-21-00 Phase III 4 countries AstraZeneca AB
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted
  2023-503298-39-00 Phase III 11 countries AstraZeneca AB
• Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept Ended
  2025-521800-22-00 Phase IV 1 country Oslo University Hospital HF

Showing 73–96 of 111 trials